
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT
- About
Sera Prognostics Inc (SERA)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SERA (1-star) is a SELL. SELL since 1 days. Profits (-22.41%). Updated daily EoD!
1 Year Target Price $2.75
1 Year Target Price $2.75
2 | Strong Buy |
0 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 44% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.64M USD | Price to earnings Ratio - | 1Y Target Price 2.75 |
Price to earnings Ratio - | 1Y Target Price 2.75 | ||
Volume (30-day avg) 2 | Beta 0.99 | 52 Weeks Range 1.37 - 9.13 | Updated Date 08/15/2025 |
52 Weeks Range 1.37 - 9.13 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.85 |
Earnings Date
Report Date 2025-08-06 | When - | Estimate -0.23 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -54823.53% |
Management Effectiveness
Return on Assets (TTM) -23.42% | Return on Equity (TTM) -44.24% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45830202 | Price to Sales(TTM) 792.96 |
Enterprise Value 45830202 | Price to Sales(TTM) 792.96 | ||
Enterprise Value to Revenue 424.35 | Enterprise Value to EBITDA -0.61 | Shares Outstanding 37094100 | Shares Floating 24996751 |
Shares Outstanding 37094100 | Shares Floating 24996751 | ||
Percent Insiders 10.87 | Percent Institutions 64.58 |
Upturn AI SWOT
Sera Prognostics Inc
Company Overview
History and Background
Sera Prognostics Inc. was founded in 2010 and is focused on improving maternal and fetal health through innovative diagnostic testing. The company went public in 2021.
Core Business Areas
- PreTRM Test: A blood test predicting the risk of spontaneous preterm birth. Its intended to help clinicians make informed decisions about patient care.
Leadership and Structure
Gregory C. Critchfield, M.D., M.S. is the Chairman, President, and CEO. The company has a board of directors and operates with a functional organizational structure.
Top Products and Market Share
Key Offerings
- PreTRM Test: A blood test that predicts a woman's risk of spontaneous preterm birth. Revenue data specific to the PreTRM test is not publicly broken out. Competitors include traditional methods of assessing preterm birth risk, such as assessing risk factors during prenatal visits and ultrasound to measure cervical length.
Market Dynamics
Industry Overview
The industry focuses on maternal and fetal health diagnostics, addressing unmet needs in predicting and preventing pregnancy complications. There's a growing demand for advanced diagnostic solutions.
Positioning
Sera Prognostics aims to be a leader in predicting preterm birth risk with its PreTRM test. Their competitive advantage lies in its predictive accuracy. They are also pursuing market development efforts, including partnerships to integrate their test into standard clinical practice.
Total Addressable Market (TAM)
The estimated TAM for preterm birth prediction is several billion dollars globally. Sera Prognostics is positioning itself to capture a significant share through increased adoption of its PreTRM test.
Upturn SWOT Analysis
Strengths
- Proprietary technology in preterm birth prediction
- Published clinical validation data
- Focus on an unmet medical need
Weaknesses
- Limited commercial adoption
- Reliance on a single product (PreTRM)
- High cash burn
Opportunities
- Expanding insurance coverage and reimbursement
- Partnering with large healthcare systems
- Developing additional maternal health diagnostics
Threats
- Competition from alternative diagnostic methods
- Regulatory hurdles
- Slow adoption by clinicians and patients
Competitors and Market Share
Key Competitors
- NXGN
- MTBC
Competitive Landscape
Sera Prognostics competes with traditional assessment methods and other diagnostic companies. Its advantage lies in the published data supporting the PreTRM test's predictive ability. Disadvantages include limited commercial traction and competition.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by increased sales of the PreTRM test.
Future Projections: Future growth is dependent on increased adoption of the PreTRM test, expanding insurance coverage, and potential new product development. Analyst estimates should be consulted for specific projections.
Recent Initiatives: Recent initiatives include partnerships with healthcare providers and efforts to expand insurance coverage.
Summary
Sera Prognostics has the potential to become a key player in the field of predictive maternal health diagnostics. The PreTRM test addresses a critical unmet need, but the company faces challenges related to commercial adoption, competition, and financial stability. Successful execution of its growth strategy is vital for long-term success and it needs to look out for increased cash burn.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, press releases, analyst reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investing in Sera Prognostics involves risks, including the potential loss of capital.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Sera Prognostics Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2021-07-15 | President, CEO & Director Ms. Evguenia Lindgardt M.B.A. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 63 | Website https://www.sera.com |
Full time employees 63 | Website https://www.sera.com |
Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.